TY - JOUR
T1 - Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia
AU - Zhornitsky, Simon
AU - Stip, Emmanuel
AU - Pampoulova, Tania
AU - Rizkallah, Élie
AU - Lipp, Olivier
AU - Bentaleb, Lahcen Aït
AU - Chiasson, Jean Pierre
AU - Potvin, Stéphane
PY - 2010/10/15
Y1 - 2010/10/15
N2 - Extrapyramidal symptoms (EPS) such as parkinsonism, dystonia, dyskinesia, and akathisia are conditions of impaired motor function, which are associated with chronic antipsychotic treatment in schizophrenia. In addition, EPS is often exacerbated by psychoactive substance (PAS) abuse, which is frequently observed in this population. Few studies, however, have investigated the contribution of PAS abuse on EPS in PAS-abusers without comorbid psychosis. This study compared the occurrence of EPS in outpatient schizophrenia patients with (DD group; n 5 36) and without PAS abuse (SCZ group; n 5 41) as well as in nonschizophrenia PAS abusers undergoing detoxification [substance use disorder (SUD) group; n 5 38]. Psychiatric symptoms were measured using the Positive and Negative Syndrome Scale and the Calgary Depression Scale for schizophrenia. Extrapyramidal symptoms were evaluated with the Extrapyramidal Symptoms Rating Scale and the Barnes Akathisia Scale. SUD diagnoses were complemented with urine drug screenings. We found that DD patients exhibited significantly more parkinsonism than SCZ patients. Our subanalyses revealed that cocaine and alcohol abuse/dependence was responsible for the increase in parkinsonism in DD patients. Additionally, we found that SUD individuals exhibited significantly more akathisia than SCZ patients. In these latter individuals, subanalyses revealed that alcohol and cannabis abuse/dependence was responsible for the increase in akathisia. Our results suggest that PAS abuse is a contributor to EPS in individuals with and without schizophrenia.
AB - Extrapyramidal symptoms (EPS) such as parkinsonism, dystonia, dyskinesia, and akathisia are conditions of impaired motor function, which are associated with chronic antipsychotic treatment in schizophrenia. In addition, EPS is often exacerbated by psychoactive substance (PAS) abuse, which is frequently observed in this population. Few studies, however, have investigated the contribution of PAS abuse on EPS in PAS-abusers without comorbid psychosis. This study compared the occurrence of EPS in outpatient schizophrenia patients with (DD group; n 5 36) and without PAS abuse (SCZ group; n 5 41) as well as in nonschizophrenia PAS abusers undergoing detoxification [substance use disorder (SUD) group; n 5 38]. Psychiatric symptoms were measured using the Positive and Negative Syndrome Scale and the Calgary Depression Scale for schizophrenia. Extrapyramidal symptoms were evaluated with the Extrapyramidal Symptoms Rating Scale and the Barnes Akathisia Scale. SUD diagnoses were complemented with urine drug screenings. We found that DD patients exhibited significantly more parkinsonism than SCZ patients. Our subanalyses revealed that cocaine and alcohol abuse/dependence was responsible for the increase in parkinsonism in DD patients. Additionally, we found that SUD individuals exhibited significantly more akathisia than SCZ patients. In these latter individuals, subanalyses revealed that alcohol and cannabis abuse/dependence was responsible for the increase in akathisia. Our results suggest that PAS abuse is a contributor to EPS in individuals with and without schizophrenia.
KW - Antipsychotics
KW - Extrapyramidal symptoms
KW - Schizophrenia
KW - Substance use disorders
UR - http://www.scopus.com/inward/record.url?scp=78649249136&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78649249136&partnerID=8YFLogxK
U2 - 10.1002/mds.23227
DO - 10.1002/mds.23227
M3 - Article
C2 - 20669315
AN - SCOPUS:78649249136
SN - 0885-3185
VL - 25
SP - 2188
EP - 2194
JO - Movement Disorders
JF - Movement Disorders
IS - 13
ER -